Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437645 | 1.00 | TDP1 (0.41) | TDP1MAPTCACNA1BAPBA1MEN1 | |
| SCHEMBL5438321 | 1.00 | TDP1 (0.41) | TDP1MAPTCACNA1BAPBA1MEN1 | |
| SCHEMBL905193 | 0.90 | — | — | |
| SCHEMBL28496420 | 0.90 | — | — | |
| SCHEMBL1110727 | 0.90 | — | — | |
| SCHEMBL3252675 | 0.81 | TDP1 (0.38) | TDP1MAPTCACNA1BAPBA1MEN1 | |
| SCHEMBL10458659 | 0.81 | TDP1 (0.41) | TDP1MAPTCACNA1BAPBA1TSHR | |
| Propionic Acid SCHEMBL14122393 | 0.81 | TDP1 (0.41) | TDP1MAPTCACNA1BAPBA1MEN1 | |
| SCHEMBL10347234 | 0.78 | CYP1A2 (0.44) | TDP1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL27618763 | 0.78 | TDP1 (0.42) | TDP1MAPTCACNA1BAPBA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205433-B2 | Crystal of amino acid ester salt and process for producing the same | AJINOMOTO CO., INC. (JP) | 2007-04-17 | — | — | US | claimed |
| US-20050197396-A1 | Crystal of amino acid ester salt and process for producing the same | AJINOMOTO CO. INC (JP) | 2005-09-08 | — | — | US | claimed |
| EP-1541546-A1 | CRYSTAL OF AMINO ACID ESTER SALT AND PROCESS FOR PRODUCING THE SAME | Ajinomoto Co., Inc. (JP) | 2005-06-15 | — | — | EP | claimed |
| US-7205433-B2 | Crystal of amino acid ester salt and process for producing the same | AJINOMOTO CO., INC. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050197396-A1 | Crystal of amino acid ester salt and process for producing the same | AJINOMOTO CO. INC (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1541546-A1 | CRYSTAL OF AMINO ACID ESTER SALT AND PROCESS FOR PRODUCING THE SAME | Ajinomoto Co., Inc. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197396-A1 | Crystal of amino acid ester salt and process for producing the same | SLC43A1, AAAS, AARS1 | GRIN2D 1442/4885GRIN3B 1234/4885GRIN1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.